Zacks Research Analysts Lower Earnings Estimates for IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Investment analysts at Zacks Research lowered their Q1 2025 EPS estimates for Iovance Biotherapeutics in a research note issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of ($0.26) for the quarter, down from their prior forecast of ($0.25). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.37) EPS.

Several other research firms have also weighed in on IOVA. The Goldman Sachs Group lowered their price objective on shares of Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Piper Sandler decreased their price target on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating for the company in a research note on Friday, February 28th. Robert W. Baird cut their price objective on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Friday, February 28th. Truist Financial decreased their target price on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $20.25.

Iovance Biotherapeutics Stock Performance

Shares of IOVA stock opened at $3.63 on Monday. The company has a market cap of $1.19 billion, a P/E ratio of -2.44 and a beta of 0.93. Iovance Biotherapeutics has a fifty-two week low of $3.42 and a fifty-two week high of $15.50. The stock has a 50 day simple moving average of $5.08 and a two-hundred day simple moving average of $7.70.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The firm had revenue of $73.69 million during the quarter, compared to analyst estimates of $72.17 million.

Institutional Trading of Iovance Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AlphaQuest LLC lifted its holdings in shares of Iovance Biotherapeutics by 63.6% in the fourth quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 1,794 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in Iovance Biotherapeutics in the 4th quarter valued at $36,000. GF Fund Management CO. LTD. purchased a new stake in Iovance Biotherapeutics in the 4th quarter valued at $47,000. One68 Global Capital LLC purchased a new position in Iovance Biotherapeutics during the 4th quarter worth $74,000. Finally, Quarry LP bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter worth $74,000. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.